VR Logo

NeoGenomics Inc. (NEO) download report


Healthcare | Diagnostics Services

NeoGenomics Inc. (NEO) Premium Coverage

53 Stocks to buy right now

Join Value Research Stock Advisor now and be among the first to discover Stock Ideas

ajax-loader
Please wait...

ajax-loader
Please wait...

ajax-loader
Please wait...

ajax-loader
Please wait...

ajax-loader
Please wait...

About The Company

Business: NeoGenomics, Inc. operates a network of cancer-focused testing laboratories in the United States, Europe, and Asia.

IPO Date: 02-Nov-1999

Chair of the Board & Interim CEO: Ms. Lynn A. Tetrault Esq., J.D.

Pres & COO of Lab Operations: Mr. George A. Cardoza

Listing: NASDAQ: NEO

Country: United States

Headquarters: Fort Myers, FL

Website: https://www.neogenomics.com

Key Facts

Market cap: $1,299.25 Mln

Revenue (TTM): $485.97 Mln

Earnings (TTM): $-35.64 Mln

Cash: $481.43 Mln

Total Debt: $613.20 Mln

Insider's Holding: 2.75%

Liquidity: Low

52 Week range: $6.85 - 54.74

Shares outstanding: 124,758,000

10 Years Aggregate:

  • CFO: $99.98 Mln
  • EBITDA: $215.87 Mln
  • Net Profit: $0.60 Mln

Stock Performance

Time Period NeoGenomics (NEO) S&P BSE Sensex* S&P Small-Cap 600*
YTD-70.081.03-11.58
1 month21.988.638.86
3 months0.397.33-2.19
1 Year-78.508.43-6.23
3 Years-26.2217.069.73
5 Years1.9912.777.72
10 Years16.7512.8310.81
As on 05-Aug-2022 *As on 08-Aug-2022
Year NeoGenomics (NEO) S&P Small-Cap 600 S&P BSE Sensex
2021-36.6325.2721.99
202084.079.5715.75
2019131.9620.8614.38
201842.05-9.705.87
20173.3811.7327.91
20168.8924.741.95
201588.73-3.36-5.03